# CANADIAN CANCER TRIALS GROUP

## **RADIATION FORUM**

#### **MEETING AGENDA**

CHELSEA HOTEL, TORONTO, ON ROOM: WREN FRIDAY, APRIL  $28^{TH}$ , 2017 - 8:00 am - 12:00 pm

CHAIR: M. MCKENZIE
SENIOR INVESTIGATOR: WENDY PARULEKAR
STUDY COORDINATOR: ALEXANDER MONTENEGRO & KATE WHELAN

#### CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

### Learning Objectives:

- To understand and address, through clinical and translational research, the disease burden associated with solid tumours and haematological malignancies treated with radiotherapy in Canada.
- To review recent developments in the understanding of molecular biology of cancers treated with radiotherapy.
- To update, review, and discuss recent results of clinical studies involving radiotherapy conducted by the Canadian Cancer Trials Group or national/international collaborators.
- To provide mentoring opportunities for investigators new to clinical trial research.
- To understand and apply new clinical trial methodologies in the field of clinical research.

8:00 am	Welcome	M. McKenzie	
Updates on CCTG studies pending of activation			
8:05 am	Randomized Phase II Study of Cisplatin + RT vs Durvalumab + RT followed by Maintenance Durvalumab vs Durvalumab plus RT followed by Maintenance Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Ca (LA-OSCC). <b>HN.9</b>	K. Sultanem	
8:15 am	A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma. <b>HN.10</b>	S. Bratman	
8:25 am	<b>TAILOR RT:</b> A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer. <b>MA.39</b>	T. Whelan	
8:35 am	A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases <b>CE.7</b>	D. Roberge	
CCTG Led Closed trials			
8:45 am	HDR brachytherapy in intermediate risk CaP. PR.15	E. Vigneault	

CCTG I	Led Open trials		
8:55 am	Phase II randomized study comparing HDR vs LDR monotherapy in localized prostate cancer. <b>PR.19</b>	G. Morton/ E. Vigneault	
9:05 am	Randomized study of single 8 Gy versus BSC for symptomatic primary or metastatic liver cancer. <b>HE.1</b>	L. Dawson	
9:15 am	SBRT vs. Conventional Palliative Radiotherapy for Spinal Metastases. <b>SC.24</b>	A. Sahgal	
9:25 am	Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in BRAF Mutation–Positive Malignant Melanoma and brain metastases. <b>IND.224</b>	A. Sahgal	
CCTG I	Intergroup Open trials		
9:35 am	Preoperative Chemoradiotherapy vs. Preoperative Chemotherapy for Resectable Gastric Cancer. <b>GA.1</b>	R. Wong / J. Ringash	
9:40 am	Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases. <b>CEC.5</b>	N. Laperriere	
9:45 am	Coffee Break		
	on previously discussed studies/ proposals		
10:00 am	Phase II of Immunotherapy +/-Stereotactic Body Radiotherapy for Metastatic Soft Tissue Sarcoma	P. Wong	
<u>New St</u> 10:05 am	udy proposals  External Beam Radiotherapy + Brachytherapy boost vs External Bea Radiotherapy + HDR Brachy boost + short course hormonal therapy		
	intermediate risk prostate cancer		
10:15 am	RADBRI: SBRT prior to liver transplantation for hepatocellular carcinoma versus no intervention in patients not eligible to transarterial	L. Dawson	
10:25 am	Phase II comparing 3- v.s. 5- fraction SBRT in Renal Cell Carcinom	a W. Chu	
10:35 am	Randomized Phase II Trial of Local Ablative Therapy for Hormone-S Oligometastatic Prostate Cancer	Sensitive P. Cheung	
10:45 am	EMBRACE II: Single arm study of image-guided IMRT and adaptive brachytherapy plus chemotherapy in advanced cervix cancer	I. Fortin	
10:55 am	5STAR: 5 fractions of pelvic SABR with intraprostatic SABR boost	A. Loblaw	
11:05 am	SBRT: Where to house SBRT protocols	R. Wong	
11:15 am	Post operative SBRT for spinal metastasis comparing conventional radiation therapy (20Gy/5 fx) vs SBRT	L. Masucci	
11:25 am	Activities of the Radiation Oncology Quality Assurance Committee	A. Nichol	
11:35 am	CCTG Radiotherapy Strategic Agenda M.	M. McKenzie/ W. Parulaker	
12:00 pm	Meeting adjourned.		